In this NutraIngredients analysis, industry experts, including Scott Mazza of Vitality CBD, address the uncertain regulatory outlook for CBD and minor cannabinoids heading into 2025, arguing that the sector needs clear, enforceable standards rather than blanket product bans. Mazza emphasizes that regulatory ambiguity harms both responsible manufacturers and consumers, particularly as lawmakers scrutinize hemp-derived cannabinoids more closely. The article positions thoughtful regulation as essential for product safety, scientific progress, and the long-term legitimacy of the CBD industry.

In an article for NutraIngredients, Scott Mazza comments on the one-year extension of the 2018 Farm Bill, warning that the delay prolongs regulatory uncertainty around CBD and hemp-derived cannabinoids in the U.S. market. He explains that postponing Farm Bill reform leaves unresolved issues such as the legality of delta-8 THC, complicates long-term planning for producers, and slows innovation across the hemp industry. Mazza argues that clearer federal guidance is urgently needed to provide stability, protect consumers, and support sustainable growth while policymakers continue to debate the future regulatory framework.

This regulatory analysis examines growing congressional pressure on the FDA over its prolonged inaction on hemp-derived CBD, including an investigation led by the U.S. House Oversight Committee. Scott Mazza of Vitality CBD argues that regulatory paralysis has enabled bad actors and unsafe products to proliferate, calling for clear federal oversight on CBD, dietary supplements, and Delta-8. The article frames forthcoming FDA decisions as critical to restoring consumer safety, industry credibility, and regulatory accountability.

In this year-in-review analysis, NutraIngredients examines how the U.S. CBD market in 2022 shifted away from hype toward scientific validation, regulatory scrutiny, and mainstream acceptance. Scott Mazza of Vitality CBD highlights growing clinical evidence, particularly in anxiety, women’s health, and recovery, as a key driver of consumer trust and industry maturity. The article positions science-led companies and clearer regulation as central to CBD’s long-term credibility and integration into wellness and sports markets.